Metformin Use Tied to Lower Incidence of Death, Long COVID After COVID-19
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 19, 2024 -- After severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, prevalent metformin use is associated with a slightly lower incidence of death or postacute sequalae of SARS-CoV-2 (PASC), according to a study published online Sept. 17 in Diabetes Care.
Steven G. Johnson, Ph.D., from the University of Minnesota in Minneapolis, and colleagues conducted a retrospective cohort analysis using N3C and PCORnet electronic health record databases to examine the incidence of PASC among metformin-exposed individuals versus individuals taking other diabetes medications. PASC was defined in two ways: PASC-U09.9, which was a U09.9 diagnosis code within 180 days of the index event, and by computable phenotype in each dataset (PASC-N3C and PASC-PCORnet).
The researchers found that the hazard ratio for death or PASC-U09.9 was 0.79 (95 percent confidence interval [CI], 0.71 to 0.88), and the hazard ratio for death or PASC-N3C was 0.85 (95 percent CI, 0.78 to 0.92) in the N3C database. The hazard ratio for death or PASC-U09.9 was 0.87 (95 percent CI, 0.66 to 1.14), and the hazard ratio for death or PASC-PCORnet was 1.04 (95 percent CI, 0.97 to 1.11) in PCORnet. By diagnosis code, incident PASC was 1.6 versus 2.0 percent for metformin and comparator in the N3C, and 2.1 versus 2.5 percent in PCORnet. By computable phenotype, incidence was 4.8 and 5.2 percent for metformin and comparator in N3C, respectively, and was 24.7 versus 26.1 percent in PCORnet.
"These data support a mildly beneficial role of metformin on chronic SARS-CoV-2 outcomes in people with diabetes," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Further Support and Information on COVID-19
Read this next
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 -- For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.